Drug intelligence / Profile preview

PKY001

Development stage: Unknown
Lead developer: Protheragen
Modality: Small Molecules
Administration: Oral

Overview

PKY001 is a small molecule inhibitor targeting the YAP/TEAD transcription factor complex, currently in Phase I clinical development for the treatment of solid tumors. Developed by Protheragen, the drug acts on the Hippo signaling pathway, a critical regulator of cell proliferation and apoptosis that is frequently hijacked in oncogenesis. By disrupting the interaction between the transcriptional co-activator YAP (Yes-associated protein) and TEAD (TEA domain family member) proteins, PKY001 prevents the transcription of genes that drive tumor growth, survival, and metastasis. This mechanism is particularly relevant in cancers characterized by Hippo pathway mutations or YAP overexpression, offering a potential therapeutic strategy for patients with advanced solid malignancies.

Other names: PKY001PKY-001PKY 001

Targets

TEAD4

Beyond the preview

Go deeper on PKY001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PKY001.

Explore the full profile